三生制药（01530）于2026年1月5日发布12月股份变动月报，报告期为2025年12月1日至12月31日。公告显示，公司法定股本维持不变，仍为50,000,000,000股普通股，面值每股USD 0.00001，总额USD 500,000。
本月已发行股份（不含库存股）自上月的2,432,833,912股增加至2,538,005,412股，总增幅为105,171,500股。其中，2,000股来自根据股份期权计划行使购股权所新增的普通股，行使价格为每股7.62港元，合计募集资金15,240港元；另外105,169,500股来自12月9日完成的配售交易，配售价为每股29.62港元，占经发行后已发行股份总数约4.14%。
报告期内，公司无已购回、赎回或注销股份的记录。截至12月31日，公司已发行股份总数增至2,538,005,412股。公司同时确认，相关发行及股份变动均已获得董事会正式授权，并遵照香港联交所《上市规则》及有关法律合规进行。
本次公告由公司秘书黎少娟签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.